Bank of America Corp DE Reduces Holdings in Artivion, Inc. (NYSE:AORT)

Bank of America Corp DE decreased its holdings in Artivion, Inc. (NYSE:AORT - Free Report) by 2.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 404,006 shares of the company's stock after selling 9,611 shares during the quarter. Bank of America Corp DE owned about 0.96% of Artivion worth $11,551,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in AORT. Smartleaf Asset Management LLC lifted its stake in shares of Artivion by 236.7% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company's stock worth $32,000 after buying an additional 786 shares during the period. R Squared Ltd purchased a new position in Artivion in the 4th quarter worth $39,000. Arcadia Investment Management Corp MI acquired a new stake in Artivion during the 4th quarter worth about $43,000. Venturi Wealth Management LLC acquired a new stake in Artivion during the 4th quarter worth about $78,000. Finally, KBC Group NV grew its stake in Artivion by 80.4% during the 4th quarter. KBC Group NV now owns 2,813 shares of the company's stock valued at $80,000 after purchasing an additional 1,254 shares during the last quarter. 86.37% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

AORT has been the subject of a number of research reports. Needham & Company LLC reaffirmed a "buy" rating and set a $32.00 target price on shares of Artivion in a report on Tuesday, May 6th. Stifel Nicolaus decreased their price objective on shares of Artivion from $33.00 to $30.00 and set a "buy" rating for the company in a research note on Tuesday, February 25th. Citizens Jmp raised shares of Artivion to a "strong-buy" rating in a report on Tuesday, May 6th. Finally, JMP Securities reissued a "market outperform" rating and set a $33.00 target price on shares of Artivion in a report on Tuesday, May 6th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $31.40.

Insider Transactions at Artivion

In other Artivion news, SVP Jean F. Holloway sold 18,020 shares of the stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $23.61, for a total transaction of $425,452.20. Following the transaction, the senior vice president now directly owns 197,184 shares of the company's stock, valued at $4,655,514.24. This trade represents a 8.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Anthony B. Semedo sold 2,600 shares of the business's stock in a transaction dated Friday, May 23rd. The stock was sold at an average price of $28.47, for a total transaction of $74,022.00. Following the sale, the director now directly owns 33,059 shares of the company's stock, valued at $941,189.73. This represents a 7.29% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 56,666 shares of company stock valued at $1,463,039 in the last ninety days. 7.60% of the stock is currently owned by corporate insiders.

Artivion Stock Performance

Artivion stock traded up $0.73 during mid-day trading on Tuesday, hitting $29.34. The company had a trading volume of 150,376 shares, compared to its average volume of 325,902. The company has a current ratio of 1.88, a quick ratio of 1.33 and a debt-to-equity ratio of 0.71. Artivion, Inc. has a 12-month low of $21.97 and a 12-month high of $32.33. The company's fifty day moving average is $25.22 and its 200-day moving average is $27.34. The company has a market capitalization of $1.25 billion, a price-to-earnings ratio of -1,466.75 and a beta of 1.54.

Artivion (NYSE:AORT - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported $0.06 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.12 by ($0.06). The firm had revenue of $98.98 million for the quarter, compared to analysts' expectations of $94.81 million. Artivion had a positive return on equity of 5.15% and a negative net margin of 0.22%. Equities research analysts predict that Artivion, Inc. will post 0.37 EPS for the current year.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.